Prevention & lipidsCohort study
Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
- Nationwide registry-based cohort study
- nationwide registers
Authors' conclusion
Possible associations between elevated long-term cardiovascular risk and increasing dosage of ADHD treatment use in a young patient group should warrant further investigation.
Study context
- Population
- Adults first-time initiated on attention-deficit/hyperactivity disorder (ADHD) treatment, 1998–2020; exposure determined 1 year after first claimed prescription
- Participants
- 26,357 / 31,211 / 15,696
- Exposure
- ≥1 defined daily dose (DDD)/day vs prior use of ADHD treatment
- Prior usersn = 26,357reference
- <1 DDD per dayn = 31,211
- ≥1 DDD per dayn = 15,696
- Outcome
- ACS, stroke, HF and their composite
- Follow-up
- 10-year
Main finding
As reported in the abstract
Standardized 10-year absolute risk
≥1 DDD per day
2.1% [95% CI: 1.8%-2.4%]
Stroke · HF 1.2% [95% CI: 0.9%-1.4%] · Composite 3.9% [95% CI: 3.4%-4.3%] · ACS 1.0% [95% CI: 0.8%-1.2%]
Prior users
1.7% [95% CI: 1.5%-1.9%]
Stroke · HF 0.7% [95% CI: 0.6%-0.8%] · Composite 3.0% [95% CI: 2.8 %-3.2%] · ACS 0.9% [95% CI: 0.8%-1.0%]
≥1 DDD per day vs Prior usersRisk ratio (95% CI)
stroke
1.2(1.0–1.5)
HF
1.7(1.3–2.2)
composite
1.3(1.1–1.5)
Observational data: associations, not effects.
Original publication
Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. J Am Coll Cardiol. Published 14 May 2024. doi:10.1016/j.jacc.2024.03.375
Summarised from the published abstract; every number is checked against it